Medimibi vs Tetrofosmin: Side-by-Side Comparison
Quick answer: Medimibi and Tetrofosmin are both radiopharmaceutical (myocardial perfusion imaging agent) used for similar indications. They share a mechanism of action but differ in dosing, half-life, side-effect profile, and clinical preferences. Switching between them is a clinical decision.
Side-by-side comparison
| Feature | Medimibi | Tetrofosmin |
|---|---|---|
| Drug class | Radiopharmaceutical (myocardial perfusion imaging agent) | Radiopharmaceutical (myocardial perfusion imaging agent) |
| ATC code | V09GA01 | V09GA02 |
| Primary indications | Myocardial perfusion imaging, Parathyroid imaging | Myocardial perfusion imaging, Diagnosis of coronary artery disease |
| Mechanism | Technetium-99m sestamibi is a lipophilic cation that accumulates in mitochondria for SPECT imaging | Lipophilic cationic Tc-99m-labeled complex that accumulates in viable myocardial tissue proportional to blood flow |
| Common dose | 185-1110 MBq IV depending on protocol | 185-740 MBq IV (Tc-99m labeled) |
| Detail page | Medimibi details → | Tetrofosmin details → |
How to choose between Medimibi and Tetrofosmin
Both medicines belong to the same therapeutic class and address overlapping indications. Selection between them depends on:
- Patient-specific factors: age, kidney and liver function, other medications, allergies, comorbidities
- Specific clinical indication: some class members are preferred for particular conditions or guideline recommendations
- Dosing preference: once-daily vs twice-daily, oral vs injectable, food requirements
- Tolerability: individual side-effect profiles vary even within a class
- Drug interactions: patient's other medications may interact differently with each option
- Cost and availability: generic availability, insurance coverage, regional access
Should you switch?
Switching between class members is a clinical decision, not a self-help one. Reasons your prescriber may consider switching include:
- Inadequate response to current medication
- Side effects affecting quality of life
- New drug interactions due to a recently added medication
- Cost or availability changes
- Updated guidelines favoring a different option
Never switch medications, change dose, or stop without consulting your prescriber.
Related
All Radiopharmaceutical (myocardial perfusion imaging agent) on iMedic · Medimibi full details · Tetrofosmin full details
Frequently asked questions
Is Medimibi better than Tetrofosmin?
Neither is universally 'better.' They are both radiopharmaceutical (myocardial perfusion imaging agent) with similar mechanisms of action. The right choice depends on the specific clinical situation, patient factors, dosing preferences, drug interactions, and tolerability. Discuss with your prescriber.
Can I switch from Medimibi to Tetrofosmin?
Switching is possible but should be done under clinical supervision. Different class members may not be interchangeable on a 1:1 dose basis, and tapering or transition strategies vary. Never switch on your own.
Do Medimibi and Tetrofosmin have the same side effects?
They share class-wide side-effect tendencies but differ in individual profiles. Some patients tolerate one better than the other. Specific frequency and severity of side effects can be found on each medicine's individual page.
Are Medimibi and Tetrofosmin available as generics?
Generic availability depends on patent status in your country. Most well-established class members are available generically and are clinically equivalent to brand-name versions.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.